Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Celltrion : says trial shows antibody COVID-19 treatment to be safe and effective

06/13/2021 | 09:51pm EDT

SEOUL (Reuters) - South Korean drugmaker Celltrion Inc on Monday announced positive results for its experimental antibody COVID-19 treatment that it said was safe and reduced the treatment period by nearly five days in Phase 3 global clinical trials.

The trials, which involved 1,315 participants, have taken place since January in 13 countries, including in South Korea, the United States, Spain and Romania, Celltrion said in a statement.

The treatment slowed severe symptoms of COVID-19 in more than 70% of patients, including the high-risk group with underlying conditions. It also cut the recovery period by 4.9 days, the company said.

In February South Korea, granted conditional approval to the antibody treatment, making it the first locally made coronavirus treatment in the country to win such approval. The company said it would seek full authorization based on the trial results.

Celltrion shares rose as much as 5.6% in Monday morning trade, compared with a 0.3% drop in the wider market.

(Reporting by Sangmi Cha, additional reporting by Joyce Lee. Editing by Gerry Doyle)

By Sangmi Cha


ę Reuters 2021
All news about CELLTRION, INC.
08/02MARKET CHATTER : Celltrion Healthcare Secures Orders for Anticancer Biosimilars ..
MT
07/22Inhalon Biopharma, Inc. Collaborates with Celltrion, Inc. to Develop Nebulize..
CI
07/19EU evaluates Sobi arthritis drug to treat COVID-19 with pneumonia
RE
07/14KOSPI COMPOSITE INDEX : South Korean Stocks End Two-Day Winning Streak over Infl..
MT
07/13MARKET CHATTER : Celltrion's COVID-19 Antibody Treatment Lowers Severe Infection..
MT
06/30EU Adds Eli Lilly's Antibodies, Four Other Drugs in COVID-19 Therapeutics Por..
MT
06/29EU picks antibody treatments, arthritis drug as preferred COVID-19 therapies
RE
06/15AstraZeneca antibody cocktail fails to prevent COVID-19 in large trial
RE
06/15MARKET CHATTER : Celltrion's COVID-19 Treatment Reduces Viral Load
MT
06/14Celltrion Rallies After Positive Data on Covid-19 Treatment
DJ
More news
Financials
Sales 2021 2 311 B 2,02 B 2,02 B
Net income 2021 741 B 0,65 B 0,65 B
Net cash 2021 365 B 0,32 B 0,32 B
P/E ratio 2021 49,9x
Yield 2021 0,01%
Capitalization 36 744 B 32 106 M 32 151 M
EV / Sales 2021 15,7x
EV / Sales 2022 13,1x
Nbr of Employees 2 072
Free-Float 69,0%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 269 500,00 KRW
Average target price 335 437,50 KRW
Spread / Average Target 24,5%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-24.93%32 166
MODERNA, INC.301.12%168 260
LONZA GROUP AG26.76%59 023
IQVIA HOLDINGS INC.39.45%47 876
SEAGEN INC.-6.81%29 694
PHARMARON BEIJING CO., LTD.88.66%26 319